Recently I wrote an article on Idenix Pharmaceuticals (IDIX), and since then the company has issued its 2nd quarter earnings with updates on their pipeline and Seth Klarman's Baupost has reported their holdings in Idenix. I will review what was discussed on the call and give my thoughts.
As I discussed in my previous article, safety is a large concern with the development of HCV drugs and poses the largest risk in an investment in Idenix. During the call, the major focus was around the update on IDX719 and pre-clinically held IDX2963.
IDX719 is the drug furthest along Idenix's development pipeline that I believe to be under-appreciated by the market. The pan-genotypic nature of IDX719 is heads...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: